Vertex Pharmaceuticals Net Income 2024

Vertex Pharmaceuticals Net Income

4.41 B USD

Vertex Pharmaceuticals Dividend yield

Ticker

VRTX

ISIN

US92532F1003

WKN

882807

In 2024, Vertex Pharmaceuticals's profit amounted to 4.41 B USD, a 21.85% increase from the 3.62 B USD profit recorded in the previous year.

The Vertex Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2029e6.34
2028e5.92
2027e5.65
2026e5.38
2025e4.82
2024e4.41
20233.62
20223.32
20212.34
20202.71
20191.18
20182.1
20170.26
2016-0.11
2015-0.56
2014-0.74
2013-0.45
2012-0.11
20110.03
2010-0.75
2009-0.64
2008-0.46
2007-0.39
2006-0.21
2005-0.2
2004-0.17

Vertex Pharmaceuticals Aktienanalyse

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching, developing, and marketing therapies for rare diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA. Since its inception, Vertex has been dedicated to pushing the boundaries of science to develop groundbreaking therapies for diseases such as cystic fibrosis and other rare genetic disorders. The company's history began in 1989 when Joshua Boger, a former employee of Merck & Co., founded the company with the goal of becoming a leading developer of therapies for rare diseases. In 1993, Vertex went public, achieving significant success. In 2012, the company announced the development of the first approved therapy for the treatment of cystic fibrosis, Kalydeco. Since then, Vertex has expanded its technology and production capabilities and continues to work on developing additional therapies for rare genetic disorders. The business model of Vertex Pharmaceuticals Inc is based on researching and developing therapies for rare genetic disorders. The company collaborates closely with patients, leading scientists, and medical professionals to develop groundbreaking therapies. Vertex is a vertically integrated company, handling everything from research and development to production and marketing in-house. This allows the company to maintain control over the entire development and production process to ensure the highest quality products. Vertex is divided into different divisions to organize its activities. The Paris research facility specializes in the development of therapies for cystic fibrosis and other rare genetic disorders. The San Diego facility focuses on the development of treatments for cancer. Additionally, the company maintains research facilities in the UK and Canada. Vertex Pharmaceuticals Inc's most well-known product is Kalydeco, the first approved medication for the treatment of cystic fibrosis targeting a specific genetic mutation. Kalydeco aims to restore the function of a specific protein in the lungs, targeting the underlying cause of the disease. The company has also developed other therapies for cystic fibrosis, including Orkambi and Symdeko, which also target genetic mutations. Vertex also has therapies for cancer in its portfolio, such as the drug VX-970 currently in clinical trials for cancer treatment. In summary, Vertex Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing therapies for rare genetic disorders. Since its founding in 1989, Vertex has continuously improved its technology and production capabilities, becoming one of the most innovative companies in the industry. The company is vertically integrated and consists of various research facilities dedicated to developing therapies for different diseases. Vertex has developed several groundbreaking medications for genetic disorders, including Kalydeco (the first approved medication for cystic fibrosis), Orkambi, and Symdeko. Vertex Pharmaceuticals Inc is an example of how research and development can play a significant role in treating rare diseases. Vertex Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Vertex Pharmaceuticals revenue by segment

In the annual report of the Vertex Pharmaceuticals share (US92532F1003, 882807, VRTX), it breaks down its revenues into 4 segments: 1. Symdeko, 2. Orkambi, 3. Kalydeco, 4. Trikafta. The Vertex Pharmaceuticals stock (WKN: 882807, ISIN: US92532F1003, Ticker Symbol: VRTX) is a leading investment for investors interested in participating in the Health Care sector.

Net Income Details

Understanding Vertex Pharmaceuticals's Profit Margins

The profit margins of Vertex Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Vertex Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Vertex Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Vertex Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Vertex Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Vertex Pharmaceuticals Stock

How much profit has Vertex Pharmaceuticals made this year?

Vertex Pharmaceuticals has made 4.41 B USD this year.

How has the profit developed compared to last year?

The profit has increased by 21.85% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Vertex Pharmaceuticals publish its earnings?

Vertex Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Vertex Pharmaceuticals?

The profits of Vertex Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Vertex Pharmaceuticals?

You can learn more about the earnings of Vertex Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Vertex Pharmaceuticals pay?

Over the past 12 months, Vertex Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vertex Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Vertex Pharmaceuticals?

The current dividend yield of Vertex Pharmaceuticals is .

When does Vertex Pharmaceuticals pay dividends?

Vertex Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vertex Pharmaceuticals?

Vertex Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Vertex Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vertex Pharmaceuticals located?

Vertex Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vertex Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vertex Pharmaceuticals from 3/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/29/2024.

When did Vertex Pharmaceuticals pay the last dividend?

The last dividend was paid out on 3/29/2024.

What was the dividend of Vertex Pharmaceuticals in the year 2023?

In the year 2023, Vertex Pharmaceuticals distributed 0 USD as dividends.

In which currency does Vertex Pharmaceuticals pay out the dividend?

The dividends of Vertex Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Vertex Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Vertex Pharmaceuticals

Our stock analysis for Vertex Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vertex Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.